Skip to main content
logo
Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
25.34
-0.17 (-0.67%)
Oct 23, 2026, 4:00 PM EDT - Market closed

Nurix Therapeutics Financials Overview

Millions USD. Fiscal year is Dec - Nov.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Revenue
701.9483.9854.5576.9938.6329.75
Revenue Growth
738.76%53.95%-29.14%99.31%29.84%66.95%
Gross Profit
367.86-232.92-167.08-112.16-145.87-86.68
Operating Income
289.66-285.67-213.03-155.06-183.87-117.89
Net Income
294.88-264.46-193.57-143.95-180.36-117.19
Earnings Per Share
2.69-3.05-2.88-2.65-3.71-2.73
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Cash & Investments
1,048592.94609.58295.33373.02432.91
Total Debt
65.3355.7328.330.6111.9613.04
Net Cash (Debt)
982.92537.21581.28264.72361.06419.87
Net Cash Growth
163.98%-7.58%119.59%-26.68%-14.01%49.34%
Net Cash Per Share
8.976.208.664.877.439.79

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Operating Cash Flow
379.31-249.47-172.58-81.37-159.81-84.37
Capital Expenditures
-9.5-14-9.27-8.4-12.24-5.66
Free Cash Flow
369.81-263.47-181.86-89.77-172.05-90.03
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
Gross Margin
52.41%-277.36%--145.69%--291.38%
Operating Margin
41.27%-340.16%-390.52%-201.41%-476.01%-396.25%
Pretax Margin
43.91%-314.00%-354.36%-186.98%-466.93%-393.49%
Profit Margin
42.01%-314.90%-354.85%-186.98%-466.93%-393.93%
FCF Margin
52.68%-313.73%-333.38%-116.60%-445.42%-302.61%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Nov '25 Nov '24 Nov '23 Nov '22 Nov '21
PS Ratio
3.9421.3428.713.9215.1243.22